Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles

Area of Science:

• Immunology
• Oncology
• Nanotechnology

Background:

• Cancer immunotherapy, including immune checkpoint inhibitors and cell therapies, shows promise but benefits only a subset of patients.
• The tumor microenvironment (TME) often suppresses effective anti-tumor immune responses.
• Understanding and manipulating the TME is crucial for improving immunotherapy efficacy.

Purpose of the Study:

• To review the development and therapeutic potential of beta-glucans and beta-glucan-based nanoparticles.
• To explore their role in modulating the tumor microenvironment (TME) for enhanced cancer immunotherapy.
• To discuss mechanisms and future applications in combination cancer therapies.

Main Methods:

• Review of scientific literature on beta-glucans, nanoparticles, and tumor microenvironment modulation.
• Analysis of mechanisms by which beta-glucans interact with immune cells and the TME.
• Discussion of emerging data on beta-glucan-based nanoparticles in cancer immunotherapy.

Main Results:

• Beta-glucans, derived from plants, fungi, and bacteria, act as pathogen-associated molecular patterns (PAMPs).
• These molecules target specific receptors on immune cells, influencing immune responses.
• Emerging evidence indicates beta-glucans and their nanoparticles can actively condition the TME.

Conclusions:

• Beta-glucans and beta-glucan-based nanoparticles represent a promising strategy for modulating the tumor microenvironment.
• This modulation can enhance the generation and delivery of anti-tumor immune responses.
• These agents hold potential for optimizing future combination cancer immunotherapies.